S&P 500   5,095.41 (-0.02%)
DOW   38,857.24 (-0.36%)
QQQ   440.63 (+0.37%)
AAPL   180.19 (-0.31%)
MSFT   414.22 (+0.14%)
META   497.48 (+1.50%)
GOOGL   138.26 (-0.14%)
AMZN   176.81 (+0.03%)
TSLA   199.04 (-1.41%)
NVDA   800.15 (+1.14%)
NIO   5.71 (-0.70%)
AMD   198.27 (+2.98%)
BABA   75.00 (+1.31%)
T   16.86 (-0.41%)
F   12.38 (-0.48%)
MU   93.48 (+3.17%)
CGC   3.25 (-1.22%)
GE   157.48 (+0.38%)
DIS   111.34 (-0.22%)
AMC   4.26 (-1.39%)
PFE   26.80 (+0.90%)
PYPL   60.67 (+0.55%)
XOM   106.09 (+1.50%)
S&P 500   5,095.41 (-0.02%)
DOW   38,857.24 (-0.36%)
QQQ   440.63 (+0.37%)
AAPL   180.19 (-0.31%)
MSFT   414.22 (+0.14%)
META   497.48 (+1.50%)
GOOGL   138.26 (-0.14%)
AMZN   176.81 (+0.03%)
TSLA   199.04 (-1.41%)
NVDA   800.15 (+1.14%)
NIO   5.71 (-0.70%)
AMD   198.27 (+2.98%)
BABA   75.00 (+1.31%)
T   16.86 (-0.41%)
F   12.38 (-0.48%)
MU   93.48 (+3.17%)
CGC   3.25 (-1.22%)
GE   157.48 (+0.38%)
DIS   111.34 (-0.22%)
AMC   4.26 (-1.39%)
PFE   26.80 (+0.90%)
PYPL   60.67 (+0.55%)
XOM   106.09 (+1.50%)
S&P 500   5,095.41 (-0.02%)
DOW   38,857.24 (-0.36%)
QQQ   440.63 (+0.37%)
AAPL   180.19 (-0.31%)
MSFT   414.22 (+0.14%)
META   497.48 (+1.50%)
GOOGL   138.26 (-0.14%)
AMZN   176.81 (+0.03%)
TSLA   199.04 (-1.41%)
NVDA   800.15 (+1.14%)
NIO   5.71 (-0.70%)
AMD   198.27 (+2.98%)
BABA   75.00 (+1.31%)
T   16.86 (-0.41%)
F   12.38 (-0.48%)
MU   93.48 (+3.17%)
CGC   3.25 (-1.22%)
GE   157.48 (+0.38%)
DIS   111.34 (-0.22%)
AMC   4.26 (-1.39%)
PFE   26.80 (+0.90%)
PYPL   60.67 (+0.55%)
XOM   106.09 (+1.50%)
S&P 500   5,095.41 (-0.02%)
DOW   38,857.24 (-0.36%)
QQQ   440.63 (+0.37%)
AAPL   180.19 (-0.31%)
MSFT   414.22 (+0.14%)
META   497.48 (+1.50%)
GOOGL   138.26 (-0.14%)
AMZN   176.81 (+0.03%)
TSLA   199.04 (-1.41%)
NVDA   800.15 (+1.14%)
NIO   5.71 (-0.70%)
AMD   198.27 (+2.98%)
BABA   75.00 (+1.31%)
T   16.86 (-0.41%)
F   12.38 (-0.48%)
MU   93.48 (+3.17%)
CGC   3.25 (-1.22%)
GE   157.48 (+0.38%)
DIS   111.34 (-0.22%)
AMC   4.26 (-1.39%)
PFE   26.80 (+0.90%)
PYPL   60.67 (+0.55%)
XOM   106.09 (+1.50%)
OTCMKTS:MPSYF

MorphoSys (MPSYF) Stock Price, News & Analysis

$70.28
0.00 (0.00%)
(As of 02/29/2024 ET)
Today's Range
$70.28
$70.28
50-Day Range
$33.25
$70.28
52-Week Range
$17.29
$70.66
Volume
N/A
Average Volume
39,348 shs
Market Capitalization
N/A
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
N/A

MPSYF stock logo

About MorphoSys Stock (OTCMKTS:MPSYF)

MorphoSys AG, a commercial-stage biopharmaceutical company, engages in the discovery, development, and commercialization of therapeutic antibodies for patients suffering from cancer and autoimmune diseases in the United States. It offers Tafasitamab, an antibody for the treatment of B cell malignancies, including diffuse large B-cell lymphoma, follicular lymphoma, and marginal zone lymphoma. The company also develops Pelabresib, a small molecule to treat myelofibrosis; Felzartamab, an antibody directed against CD38 for the treatment of anti-PLA2R-positive membranous nephropathy, an autoimmune disease; and CPI-0209, a small molecule to promote anti-tumor activity by inhibiting EZH2 and EZH1. In addition, it develops Gantenerumab, an antibody for the treatment of Alzheimer's diseases; and Otilimab, an antibody for rheumatoid arthritis. The company has a regional licensing agreement with I-Mab Biopharma to develop and commercialize felzartamab in China, Taiwan, Hong Kong, and Macau; a strategic alliance with the LEO Pharma; a joint collaboration and license agreement with Incyte Corporation to develop and commercialize MorphoSys investigational compound tafasitamab; and a clinical collaboration with Incyte Corporation and Xencor, Inc. to investigate the combination of tafasitamab, plamotamab, and lenalidomide in patients with relapsed or refractory diffuse large B-cell lymphoma, and relapsed or refractory follicular lymphoma. MorphoSys AG was founded in 1992 and is headquartered in Planegg, Germany.

MPSYF Stock Price History

MPSYF Stock News Headlines

No headlines for this company have been tracked by MarketBeat.com
Receive MPSYF Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for MorphoSys and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Sector
Medical
Industry
Biotechnology
Sub-Industry
N/A
Current Symbol
OTCMKTS:MPSYF
Fax
N/A
Employees
544
Year Founded
N/A

Profitability

Pretax Margin
N/A

Debt

Sales & Book Value

Annual Sales
N/A

Miscellaneous

Free Float
N/A
Optionable
Not Optionable
Beta
N/A
The Best High-Yield Dividend Stocks for 2024 Cover

Looking to generate income with your stock portfolio? Use these ten stocks to generate a safe and reliable source of investment income.

Get This Free Report

Key Executives

  • Dr. Jean-Paul Kress M.D. (Age 59)
    Chairman of Management Board, MD & CEO
    Comp: $2.2M
  • Dr. Lucinda Crabtree Ph.D. (Age 45)
    CFO & Member of Management Board
  • Ms. Charlotte Lohmann (Age 54)
    Chief Legal and Human Resources Officer & Member of Management Board
  • Mr. Klaus De Wall
    Head of Accounting & Tax
  • Dr. Margit Urban
    Head of Discovery Alliances & Technologies
  • Dr. Julia Neugebauer Ph.D.
    Head of Investor Relations
  • Dr. Barbara Krebs-Pohl Ph.D.
    Chief Business Officer
  • Dr. Günter Wellnhofer
    Head of Technical Operations
  • Dr. Ralf Ostendorp
    Head of Protein Sciences & CMC
  • Dr. Harald Watzka
    Head of Alliance Management














MPSYF Stock Analysis - Frequently Asked Questions

How have MPSYF shares performed in 2024?

MorphoSys' stock was trading at $41.00 on January 1st, 2024. Since then, MPSYF shares have increased by 71.4% and is now trading at $70.28.
View the best growth stocks for 2024 here
.

How do I buy shares of MorphoSys?

Shares of MPSYF stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

This page (OTCMKTS:MPSYF) was last updated on 3/1/2024 by MarketBeat.com Staff